Lilly’s Foundayo Meets Main Goal in Late-Stage Sleep Apnea Study
Eli Lilly said its oral weight-loss drug Foundayo met the main goal in a late-stage study of adults with moderate-to-severe obstructive sleep apnea and obesity.
Eli Lilly NYSE:LLY said on Monday its oral weight-loss drug Foundayo met the main goal of a late-stage study in adults with moderate-to-severe obstructive sleep apnea and obesity.